Skip to main content

Find a clinical trial

AC-061A302

A multi-center, randomized, double-blind study to compare the efficacy and safety of cadazolid versus vancomycin in subjects with Clostridium difficile associated diarrhea (CDAD) Mickael Aoun

AMC303-01

A safety, tolerability and pharmacokinetic dose escalation expansion, Phase I/Ib study of AMC303 as monotherapy in patients with advanced or metastatic, malignant solid tumour of epithelial origin Philippe Aftimos

APR-407_EUTROC-PiSARRO

p53 Suppressor Activation in Recurrent High Grade Serous Ovarian Cancer, a Phase Ib/II Study of Systemic Carboplatin Combination Chemotherapy With or Without APR-246 Joseph Kerger

BGOG-cx1/ENGOT-cx1

Randomized double-blind phase II study comparing 3-weekly carboplatin (AUC 5 or 6) + paclitaxel 175 mg/m2 with or without concomitant and maintenance Nintedanib in advanced or recurrent cervical carcinoma. Joseph Kerger

CA209358 / CheckMate 358

Non-Comparative, Two-Cohort, Single-Arm, Open-Label, Phase 1/2 Study of Nivolumab (BMS-936558) in Subjects with Virus-Positive and Virus-Negative Solid Tumors. Ahmad Hussein Awada

1367.1

An open label, Phase Ia/Ib dose finding study with BI 894999 orally administeredonce a day in patients with advanced malignancies, with repeated administration in patients with clinical benefit Ahmad Hussein Awada

STRIVE

a phase 2, multicenter, randomized, double-blind study of the safety, tolerability and efficacy of intravenous CD101 vs intravenous caspofungin followed by oral fluconazole stept-down in the treatment of subjects with candidemia Mickael Aoun

DEBIO 1143-EOC-203

A randomized, double-blind, placebo controlled phase II trial of neoadjuvant carboplatin and paclitaxel, with or without Debio 1143 in patients with newly diagnosed advanced epithelial ovarian cancer Joseph Kerger

EMR 200647-001

Phase I, open-label, multiple-ascending dose trial to investigate the safety, tolerability, pharmacokinetics, biological and clinical activity of MSB0011359C in subjects with metastatic or locally advanced solid tumors and expansion to selected indications Ahmad Hussein Awada

EORTC 1658

Qualification of imaging methods to assess cancer drug induced interstitial lung disease (ImageILD) Konstantinos Stathopoulos

EORTC 55092

Phase IB-II, open label, multicentre feasibility study of pazopanib in combination with Paclitaxel and Carboplatin in patients with platinumrefractory/ resistant ovarian, fallopian tube or peritoneal carcinoma. Joseph Kerger

C101

Open, non-controlled, multicenter, first-in-human study for the evaluation of the safety, pharmacokinetics and preliminary antitumor activity of GM102 in patients with advanced pretreated gynecological cancer Ahmad Hussein Awada

GS-US-218-1227

A Phase 2b, Randomized, Double-Blind, Placebo-Controlled Multi-Center Study Evaluating Antiviral Effects, Pharmacokinetics, Safety, and Tolerability of GS-5806 in Hospitalized Adults with Respiratory Syncytial Virus (RSV) Infection Mickael Aoun

Intervention dyadique

Reinforcement of onco-psychological interventions by the development of psychological support for patients and their significant others

IJB_2719

A Phase 1/2, Open-Label, Dose-Escalation / Dose-Expansion, Safety and Tolerability Study of INCB059872 in Subjects With Advanced Malignancies Ahmad Hussein Awada

INCB 01158-203

A Phase 1/2 Study to Evaluate the Safety, Tolerability, and Efficacy of INCB001158 in Combination With Chemotherapy, in Subjects With Advanced or Metastatic Solid Tumors. (INCB01158-203)

IJB_2724

A Phase 1/2 Study Exploring the Safety, Tolerability, and Efficacy of INCAGN01876 in Combination With Immune Therapies in Subjects With Advanced or Metastatic Malignancies Philippe Aftimos

Sevrage Tabagique

Impact of an emotion and craving regulation intervention on smoking cessation and maintenance among oncology patients : a randomised study Darius Razavi

Intervention destinée aux parents

Children facing parental cancer : a randomized controlled study evaluating the efficacy of a psychological intervention to support parenting Darius Razavi

Follow us!

Support research

Support research

Research at the Institut Jules Bordet depends on your generosity. Make a donation today and join us in the fight against cancer.

Learn more